Page last updated: 2024-09-03

angiotensin ii, des-phe(8)- and indole-3-carbinol

angiotensin ii, des-phe(8)- has been researched along with indole-3-carbinol in 1 studies

Compound Research Comparison

Studies
(angiotensin ii, des-phe(8)-)
Trials
(angiotensin ii, des-phe(8)-)
Recent Studies (post-2010)
(angiotensin ii, des-phe(8)-)
Studies
(indole-3-carbinol)
Trials
(indole-3-carbinol)
Recent Studies (post-2010) (indole-3-carbinol)
1,5332199565716250

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Červenka, L; Doleželová, Š; Falck, JR; Husková, Z; Imig, JD; Jíchová, Š; Kompanowska-Jezierska, E; Kopkan, L; Kramer, HJ; Kujal, P; Neckář, J; Reddy, RN; Sadowski, J; Vernerová, Z1

Other Studies

1 other study(ies) available for angiotensin ii, des-phe(8)- and indole-3-carbinol

ArticleYear
Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.
    Journal of hypertension, 2016, Volume: 34, Issue:10

    Topics: 8,11,14-Eicosatrienoic Acid; Albuminuria; Angiotensin I; Angiotensin II; Animals; Blood Pressure; Cytochrome P-450 CYP1A1; Hypertension, Malignant; Indoles; Kidney; Male; Peptide Fragments; Rats; Rats, Transgenic; Renin; Renin-Angiotensin System; Time Factors

2016